On March 16, 2016 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) reported that it will present preclinical and clinical data on its extensive oncology pipeline at the 2016 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, April 16-20, 2016 at the Ernest N. Morial Convention Center, New Orleans, Louisiana (Press release, Merrimack, MAR 16, 2016, View Source [SID:1234509589]). Of particular focus will be preclinical data on the latest novel therapeutic developed from Merrimack’s nanoliposome platform and systems biology approach – MM-310, an ephrin receptor A2 (EphA2)-targeted nanoliposome delivering docetaxel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

EphA2 is a key receptor associated with poor prognosis and is shown to be overexpressed in several solid tumors including prostate, ovarian, gastric and lung cancer. In preclinical models, MM-310 has demonstrated that Merrimack’s proprietary delivery platform provides controlled biodistribution and sustained exposure of the drug at the site of the tumor. This design has shown improvement in antitumor activity while avoiding the hematologic toxicities common with docetaxel or the bleeding associated with a traditional antibody drug conjugate (ADC) format in preclinical models.

Merrimack will also present a late-breaking abstract describing in vitro and in vivo targeting effects of MM-302 in HER2 intermediate cancer cells as well as research on ONIVYDE (irinotecan liposome injection) and other targeted therapies currently in development.

Oral presentation
MM-310: a novel EphA2 targeted nanoliposome for delivery of docetaxel

Session Title: Antibody-targeted Therapy
Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Preclinical in vitro and in vivo rationale (Abstract #871)
Sunday, April 17, 2016, 4:15 PM – 6:15 PM ET

Poster Sessions
MM-310: a novel EphA2 targeted nanoliposome for delivery of docetaxel

Session Title: Targeting the Microenvironment
Nanoliposomal targeting of Ephrin receptor A2 (EphA2): Clinical Translation (Abstract #750, Poster Section 33)
Sunday, April 17, 2016, 1:00 PM – 5:00 PM ET

Session Title: Drug Delivery
Activity of an EphA2-targeted docetaxel nanoliposome in pancreatic patient-derived models as monotherapy and in combination with gemcitabine (Abstract #2069, Poster Section 15)
Monday, April 18, 2016, 1:00 PM – 5:00 PM ET

Session Title: Therapeutics
MM-310, a novel EphA2-targeted docetaxel nanoliposome (Abstract #3912, Poster Section 21)
Tuesday, April 19, 2016, 1:00 PM – 5:00 PM ET
MM-398 (ONIVYDE (irinotecan liposome injection) or "Nal-IRI"): a novel encapsulation of irinotecan in a liposomal formulation

Session Title: Drug Delivery
Differential tissue clearance results in improved therapeutic index for irinotecan liposome injection (ONIVYDE) when combined with the PARP inhibitor veliparib in preclinical cervical tumors (Abstract #2075, Poster Section 15)
Monday, April 18, 2016, 1:00 PM – 5:00 PM ET

Session Title: Targeted Therapy
Preclinical anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) + 5-FU + oxaliplatin in pancreatic cancer (Abstract #4830, Poster Section 20)
Wednesday, April 20, 2016, 8:00 AM – 12:00 PM ET
MM-302: a novel HER2 targeted liposomal doxorubicin

Session Title: Late-Breaking Research: Cancer Chemistry
HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo (Abstract #LB-061, Poster Section 12)
Sunday, April 17, 2016, 1:00 PM – 5:00 PM ET
MM-141 (istiratumab): a monoclonal antibody that acts as a tetravalent inhibitor of PI3K/AKT/mTOR

Session Title: Growth Factor Receptors and Surface Antigens as Therapeutic Targets
Istiratumab (MM-141), a bispecific antibody targeting IGF-1R and ErbB3, inhibits pro-survival signaling in vitro and potentiates the activity of standard of care chemotherapy in vivo in ovarian cancer models (Abstract #1209, Poster Section 15)
Monday, April 18, 2016, 8:00 AM – 12:00 PM ET
MM-151: an oligoclonal therapeutic consisting of a mixture of 3 fully human monoclonal antibodies designed to bind and inhibit signaling of the epidermal growth factor receptor (EGFR)

Session Title: New Drugs, Therapeutic Targets, and Treatment Approaches
MM-151 elicits broad and unique inhibition of cells harboring EGFR extracellular domain mutations —results of multiscale experiments with genome-edited cell lines (Abstract #2148, Poster Section 18)
Monday, April 18, 2016, 1:00 PM – 5:00 PM ET
Companion Therapeutics:

Session Title: Growth Factor Receptors and Surface Antigens as Therapeutic Targets
A network biology screen reveals ligand-receptor pathway connections and resistance mechanisms to RTK-directed therapies in cancer cells (Abstract #1199, Poster Section 15)
Monday, April 18, 2016, 8:00 AM – 12:00 PM ET
Preclinical Research:

Session Title: Targeting Protein Kinases, Death Pathways, and the Tumor Microenvironment
Design and engineering of TRAIL fusion proteins for cancer therapy (Abstract #3842, Poster Section 19)
Tuesday, April 19, 2016, 1:00 PM – 5:00 PM ET

On March 16, 2016 Incyte Corporation (Nasdaq: INCY) reported that ten abstracts featuring data from its emerging development portfolio will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2016 in New Orleans, Louisiana from April 16–20, 2016 (Press release, Incyte, MAR 16, 2016, View Source;p=RssLanding&cat=news&id=2149072 [SID:1234509588]). These abstracts include data from the Company’s monoclonal antibody agonist programs targeting GITR and OX40 as well as its small molecule inhibitor programs targeting LSD1, BRD (BET), PI3Kδ and JAK1.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to present the latest scientific data that underlie the potential of our emerging development portfolio at the upcoming AACR (Free AACR Whitepaper) annual meeting," stated Reid Huber, PhD, Chief Scientific Officer, Incyte. "This collection of abstracts exemplifies our discovery team’s innovative approach to cancer research, and reinforces Incyte’s commitment to the advancement of novel therapeutics which have the potential to improve and extend the lives of patients living with cancer."

In addition to these presentations, Incyte has been invited to present "IDO1 Inhibition as a Modifier of the Immune Composition of the Tumor Microenvironment and a Component of Combination Immunotherapy for Cancer," as part of an AACR (Free AACR Whitepaper) Major Symposia entitled, "Cancer Immunotherapy: Small Molecule Approaches" scheduled for Wednesday, April 20, 2016 from 10:15 a.m.–12:00 p.m., Ernest N. Morial Convention Center, Theater C, New Orleans, La.

Key abstract presentations, including Incyte-sponsored and independent investigator studies, include:

Effects of INCB052793, a Selective JAK1 Inhibitor, in Combination with Standard of Care Agents in Human Multiple Myeloma (MM) Cell Lines and Xenograft Models (Abstract #1339)
Monday April 18, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 19

Preliminary safety, efficacy, and pharmacodynamics of a highly selective PI3Kδ inhibitor, INCB050465, in patients with previously treated B-cell malignancies (Abstract #CT056)
Monday Apr 18, 2016 1:00–5:00 p.m., Halls G-J, Poster Section 13

INCAGN01949: An anti-OX40 agonist antibody with the potential to enhance tumor specific T cell responsiveness, while selectively depleting intratumoral regulatory T cells (Abstract #3204)
Tuesday, April 19, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 25

A novel agonist antibody (INCAGN01876) that targets the co-stimulatory receptor GITR (Abstract #3220)
Tuesday, April 19, 2016, 8:00 a.m. –12:00 p.m., Halls G-J, Poster Section 25

Activity of the BET Inhibitor INCB054329 in models of lymphoma (Abstract #3780)
Tuesday, April 19, 2016, 1:00–5:00 p.m., Halls G-J, Poster Section 16

The LSD1 inhibitor INCB059872 is synergistic with ATRA in models of non-APL acute myelogenous leukemia (Abstract #4696)
Wednesday, April 20, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 16

Combination of BET inhibitor INCB054329 and LSD1 inhibitor INCB059872 is synergistic for the treatment of AML in vitro and in vivo (Abstract #4702)
Wednesday, April 20, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 16

The evaluation of INCB059872, an FAD-directed Inhibitor of LSD1, in preclinical models of human small cell lung cancer (Abstract #4704)
Wednesday, April 20, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 16

Discovery of INCB059872, a novel FAD-directed LSD1 inhibitor that is effective in preclinical models of human and murine AML (Abstract #4712)
Wednesday, April 20, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 16

The BET inhibitor INCB054329 enhances the activity of checkpoint modulation in syngeneic tumor models (Abstract #4904)
Wednesday, April 20, 2016, 8:00 a.m.–12:00 p.m., Halls G-J, Poster Section 23

Full session details for AACR (Free AACR Whitepaper) 2016 can be found here.

On March 16, 2016 GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company’s business and clinical programs and announced financial results for the full year ended December 31, 2015 (Filing, Annual, GlobeImmune, 2015, MAR 16, 2016, View Source [SID:1234509586]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company continues to seek potential strategic transactions and, after a thorough process, has not identified a potential transaction to date. Cantor Fitzgerald & Co. has been retained by the Company to assist in reviewing ways to maximize stockholder value. There is not a defined timeline for the strategic review process and the review may not result in any specific action or transaction.

The Company has three ongoing clinical trials being conducted by the Company’s corporate collaborators, Gilead Sciences, Inc. and Celgene Corporation. GS-US-330-1401, the GS-4774 Phase 2 clinical trial in patients with chronic HBV infection who are currently not receiving treatment, is fully enrolled and the 24-week results are projected to be available in the second quarter of 2016. The results from a GI-6207 Phase 2 trial in subjects with medullary thyroid cancer are projected to be available in the second half of 2016. A Phase 2 clinical trial designed to investigate the safety and efficacy of evaluating GI-6301 in combination with radiation therapy in patients with chordoma is still enrolling patients.

Financial Results – Fiscal Year 2015

For the full year ended December 31, 2015, GlobeImmune reported a net loss of $2.8 million compared to $16.3 million in 2014. The decrease in net loss for 2015 was due to $1.8 million of revenue from the license of the GI-6200 program to Celgene, lower research and development expenses due to lower compensation expense, as well as no interest expense, early retirement expense associated with convertible notes and no fair-value adjustments of warrants as these costs terminated upon the closing of the Company’s initial public offering in July 2014. GlobeImmune reported a loss applicable to common stockholders of $2.8 million, or $0.48 per share, for the year ended December 31, 2015 compared to loss applicable to common stockholders of $23.4 million, or $8.04 per share, in 2014.

Research and development for proprietary programs expense for the year ended December 31, 2015 was $1.8 million compared to $2.2 million for the year ended December 31, 2014, a decrease of $0.4 million. The decrease was primarily due to a reduction in expenses related to the GI-4000 program and a decrease in salary expense due to layoffs during the third quarter. Costs of manufacturing services for 2015 were $0.3 million compared to $1.5 million in 2014. The decrease was primarily due to a decrease in expenses relating to manufacturing services for Gilead for the Phase 2 HBV trial. Costs of collaboration license and services for the year ended December 31, 2015 was $2.4 million compared to $3.5 million for the year ended December 31, 2014, a decrease of $1.1 million. The decrease was primarily due to a decrease in expenses related to the Phase 1 clinical trial for GS-4774 and reduction in salary expense due to layoffs during the third quarter. General and administrative expense for the year ended December 31, 2015 was $4.6 million compared to $4.3 million for the year ended December 31, 2014, an increase of $0.3 million. The increase was related to expenses associated with being a public company for a full year ended December 31, 2015 offset by lower travel expenses and gain on sale of property and equipment.

At December 31, 2015, GlobeImmune had cash and equivalents of $9.9 million. The Company’s major financial obligation is the remaining balance on its lease. Net of the total payments due over the remaining 36 months of the lease obligation, the Company believes it has sufficient cash to operate the company through the end of 2016 as it continues to evaluate strategic alternatives.

On March 16, 2016 Foundation Medicine, Inc. (NASDAQ:FMI) and its collaborators reported new data in a variety of tumor types at the 2016 United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place March 12-18 in Seattle (Press release, Foundation Medicine, MAR 16, 2016, View Source [SID:1234509585]). The data further strengthens the growing body of evidence across various cancers in support of integrating comprehensive genomic profiling with FoundationOne into the clinical pathology assessments of cancer patients to help inform targeted therapy utilization and improve patient care. The data presented underscore an urgent need for innovative solutions capable of accurately informing therapeutic options based on unique genomic alterations found within each patient’s tumor. Oncology case reports and series have indicated positive responses to targeted therapies for certain rare tumor types, and additional evidence supporting clinical utility is evolving to support payor coverage.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are encouraged by the latest data presented amongst the global leaders and top minds in the pathology field at USCAP," said Jeffrey S. Ross M.D., medical director of Foundation Medicine, chair of pathology at the Albany Medical Center and lead author of two of the studies. "The pathology community is essential to advancing the next generation of novel therapies and personalized treatment for cancer patients worldwide. We are honored to provide an evidence-based platform to help the oncology community identify clinically relevant genomic alterations that hold the potential to influence patient treatment options, both for therapies that are FDA approved and therapies that are being investigated in clinical trials."

Three of the posters presented at the event focused on cancers with diverse, clinically relevant alterations, many of which are undetectable with standard screening, and represent indications with unmet clinical need, including refractory and metastatic breast cancer, triple negative breast cancer (TNBC) and adult and pediatric brain tumors. Results from all three data sets point to the importance of comprehensive genomic profiling to potentially influence and personalize treatment and guide the selection of approved targeted therapies or access to novel therapies that are being investigated in clinical trials.

Key Data Highlights:

The poster presentation titled, "Pangenomic Analysis of BRAF Genomic Alterations Across All Types of Brain Tumors Reveals Expanded Opportunities for Targeted Therapies," by Zachary R. Chalmers, lead researcher, senior research associate with Foundation Medicine, and presented by Dr. Ross demonstrates the need for additional basket-type clinical trials aimed to identify BRAF genomic alterations in various types of non-melanoma cancers to further understand targeted therapy choice and efficacy. Comprehensive genomic profiling using FoundationOne was performed to search for all classes of BRAF alterations in a large series of intracranial neoplasms including adult and pediatric brain tumors, and key findings include:

142 (4.8 percent) brain tumors featured BRAF alterations including base substitutions (70 percent), fusions (25 percent) and rare amplifications and other alterations types (5 percent). Genomic alterations in BRAF are widely distributed in brain tumors with base substitutions primarily seen in high-grade gliomas and BRAF fusions in low grade gliomas

The presentation demonstrated that BRAF base substitutions and fusions can be successfully targeted with anti-BRAF and anti-MEK targeted therapies

Preliminary findings outlined in the poster presentation titled, "Genomic Alterations of MCL1 is a Predictive Biomarker of Triple Negative Status and Therapy Response in Breast Cancer," led and presented by Dr. Ross, draw attention to the vital need for comprehensive analysis of breast cancer genes and the inherent limitations of hotspot testing in uncovering potential therapy options. Two hundred patients with breast cancer underwent comprehensive genomic profiling using FoundationOne, and key findings include:

MCL1 amplification is a frequent feature in advanced stage and high grade breast cancer, and MCL1 amplified breast cancer is very seldom ERBB2 co-amplified

Of the MCL1 amplified breast cancer cases, 88 percent were high grade and 98 percent were stage IV at the time of sequencing

Of the 200 MCL1 amplified breast cancer patients, 12 (6 percent) were ERBB2 (HER2) amplified

Clinical observation across several case studies suggest that treatment with targeted therapies including sorafenib and vorinostat in heavily pre-treated MCL1 amplified breast cancer may be correlated with clinical benefit

These preliminary findings suggest that MCL1 amplified TNBC may benefit from combination targeted therapy, and warrant further investigation in a prospective clinical trial

Consistent with the other two data sets, the findings in the poster presentation titled, "The Detection of IHC-/FISH- ERBB2 Non-Amplification Mutations in 5,606 Cases of Refractory and Metastatic Breast Cancer: an Emerging Opportunity for anti-HER2 Targeted Therapies," led by Siddhartha Dalvi, MBBS, lead researcher, Albany Medical College, and presented by Dr. Ross, demonstrate the potential for missing critical information with routine hotspot sequencing tests and thus the need for comprehensive profiling with FoundationOne. Comprehensive genomic profiling was performed on 5,606 metastatic breast cancer patients, and key findings include:

ERBB2mut are responsible for nearly 20 percent of ERBB2 alterations in metastatic breast cancer, though such mutations are not detectable by routine IHC and FISH slide-based HER2 tests

698 (12.5 percent) featured ERBB2 alterations, 596 (10.6 percent) featured ERBB2 amplifications (ERBB2amp) and 137 (2.4 percent) featured ERBB2mut

Evidence that ERBB2mut driven mBC are responsive to anti-HER2 targeted therapies is steadily accumulating

On March 16, 2016 Bio-Path Holdings, Inc., (NASDAQ: BPTH) ("Bio-Path"), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery technology to develop a portfolio of targeted nucleic acid cancer drugs, reported operational and financial results for the year ended December 31, 2015 (Filing, Annual, Bio-Path Holdings, 2015, MAR 16, 2016, View Source [SID:1234509584]).

"2015 was a year of significant progress for Bio-Path," said Peter Nielsen, President and Chief Executive Officer of Bio-Path. "With two full remissions achieved in the safety segment of our Phase II trial of lead candidate BP1001 in advanced AML patients, the formation of an inaugural Scientific Advisory Board, and receiving orphan drug designation for BP1001 in AML, we are looking forward to a successful 2016."

2015 Operational Highlights:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

· Finalized the data package for the monotherapy portion of the Phase I clinical trial of Bio-Path’s lead product candidate, BP1001 (Liposomal Grb2 antisense), in blood cancers during the fourth quarter of 2015. BP1001 was well tolerated and showed signs of anti-leukemia activity and no drug-related toxicities. Among 21 evaluable patients, more than half experienced at least a 50 percent reduction in peripheral or bone marrow blasts from baseline. Additionally, several patients demonstrated transient improvement and/or stable disease. Notably, one patient with chronic myelogenous leukemia (CML) blast phase showed a significant reduction in blasts. Patient data from the Phase I clinical trial also demonstrated significant reductions in the target Grb2 protein and its downstream proteins, providing positive evidence that Bio-Path’s DNAbilizeTM neutral lipid delivery with proprietary antisense technology successfully delivers an antisense drug substance to a diseased cell to knock down the target protein.

· Received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BP1001 for the treatment of acute myeloid leukemia (AML) in the second quarter of 2015. Orphan drug status provides Bio-Path with seven years of exclusivity after receiving formal marketing approval, as well as additional development incentives.

· Performed preclinical testing of BP1001 in two additional indications—triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates. Bio-Path is rolling this initiative into a broader solid tumor testing program, including advanced ovarian cancer. The preclinical program may be expanded to include combination therapy evaluations.

· Added a second drug manufacturer, strengthening Bio-Path’s manufacturing process while increasing capability and capacity.

· Continued preclinical evaluation of a third DNAbilizeTM product. Bio-Path’s product candidate screening and development program has validated the next promising candidate, which will diversify the Company’s product pipeline. Potential indications include diffuse large B-cell lymphoma, non-small cell lung cancer, pancreatic cancer and disease candidates outside of oncology, such as autoimmune disorders.

· Formed a Scientific Advisory Board to support the advancement of Bio-Path’s clinical and preclinical therapeutic candidates. Jorge Cortes, M.D., renowned leukemia expert from The University of Texas MD Anderson Cancer Center, joined as Chairman. Amy P. Sing, M.D., a member of Bio-Path’s board of directors and Senior Director of Medical Affairs at Genomic Health, Inc., joined as a founding member.

· Presented Bio-Path’s proprietary technology and clinical trial results at an international meeting. Jorge Cortes, M.D. of The University of Texas MD Anderson Cancer Center and Chair of Bio-Path’s Scientific Advisory Board presented a poster at the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting on December 7, 2015 in Orlando, FL. Dr. Cortes discussed data from the Phase I and safety segment of the Phase II clinical trials of BP1001 in blood cancers. These data included the complete remission of two evaluable patients receiving BP1001 in combination with low-dose cytarabine (LDAC) chemotherapy.

· Presented to the medical and scientific community at the IBC’s 17th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference in San Diego. The presentation featured Bio-Path’s DNAbilizeTM technology for delivering liposome/antisense drugs and highlighted BP1001. The TIDES Summit is prominently known as the premier conference for the oligonucleotide and peptide discovery, development and manufacturing industries.

· Continued enhancement of Bio-Path’s public profile within the investment community and biopharmaceutical industry. Chief Executive Officer Peter Nielsen delivered company presentations at the 17th Annual Rodman & Renshaw Global Investment Conference in September 2015, the 14th Annual BIO Investor Forum in October 2015, Biotech Showcase 2015 Conference in San Francisco, CA in January 2016 and the 18th Annual BIO CEO & Investor Conference in New York City in February 2016.

· Established an "at-the-market" ("ATM") program during the second quarter of 2015, through which it may offer and sell up to $25 million of common stock from time to time, at Bio-Path’s discretion, through an investment banker, acting as sales agent. Sales of Bio-Path common stock under the ATM program may be made directly on or through the Nasdaq Capital Market, among other methods. As of December 31, 2015, the Company has not offered or sold any shares of common stock under the ATM program.

Recent / First Quarter 2016 Operational Highlights:

· Completed the safety segment of the Phase II clinical trial of BP1001, in combination with low-dose cytarabine (LDAC) chemotherapy, in patients with advanced AML. Of the six evaluable patients, two had a complete response and two had a partial response, with one patient continuing treatment. Bio-Path saw no adverse events attributable to BP1001 treatment.

· Entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate Bio-Path’s clinical pipeline for its ability to modulate pancreatic cancer.

Expected Upcoming Milestones:

· BP1001 in Acute Myeloid Leukemia (AML): Bio-Path is finalizing steps to commence a multi-site Phase II clinical trial assessing the efficacy of BP1001 in combination with low-dose cytarabine (LDAC) chemotherapy, which is expected to commence in the second quarter of 2016.

· BP1001 in Chronic Myelogenous Leukemia (CML): Bio-Path commenced development of a protocol for a Phase II clinical trial evaluating BP1001 in combination with frontline chemotherapy in CML patients in blast crisis, an area of unmet medical need. This clinical trial is expected to start in the second quarter of 2016.

· BP1002 (Liposomal Bcl2; L-Bcl2): Bio-Path is finalizing a preclinical package of toxicity, tissue distribution, pharmacokinetics and efficacy studies for its second product candidate, BP1002. An Investigational New Drug (IND) application will be filed with the FDA upon finalizing drug batch required for the Chemistry, Manufacturing and Controls section of the IND. Bio-Path expects that the favorable toxicity profile of BP1001 will allow for a Phase I clinical trial of BP1002 to begin at a higher dose, thus reducing the number of patients required to complete the safety phase of the trial.

2015 Financial Highlights:

· Bio-Path reported a net loss of $5.5 million for the year ended December 31, 2015, compared to a net loss of $4.5 million for the year ended December 31, 2014. The increase was primarily due to increased clinical trial expenses, manufacturing development, preclinical study costs and personnel costs associated with the addition of research and development support staff in the second half of 2014. The Company reported a net loss of $0.06 per share for the year ended December 31, 2015, compared to a net loss of $0.05 per share for the year ended December 31, 2014.

· Research and development expenses for the year ended December 31, 2015 increased to $3.0 million, compared to $1.8 million for the year ended December 31, 2014.

· General and administrative expenses for the year ended December 31, 2015 decreased to $2.5 million, compared to $2.7 million for the year ended December 31, 2014.

· As of December 31, 2015, the Company had a cash balance of $8.9 million, compared to $13.9 million at December 31, 2014. Net cash used in operating activities for the year ended December 31, 2015 was $5.0 million, compared to $3.8 million for the comparable period in 2014.

About Bio-Path’s Delivery Technology

Bio-Path’s drug delivery technology, called DNAbilize, involves microscopic-sized liposome particles that distribute nucleic acid drugs systemically and safely throughout the human body, via simple intravenous infusion. The delivery technology is applied to proprietary, single stranded (antisense) nucleic acid compounds with the potential to revolutionize the treatment of cancer and other diseases where druggable targets of disease are well characterized. The Company is currently focused on developing liposomal antisense drug candidates. Bio-Path also anticipates developing liposome tumor targeting technology, representing next-generation enhancements to the Company’s core liposome delivery technology.

About BP1001 (Liposomal Grb2 antisense)

BP1001 (Liposomal Grb2 antisense) is a neutral-charge, liposome-incorporated antisense drug substance designed to inhibit Grb2 protein expression. The protein Grb2 is essential to cancer cell signaling because it is utilized by oncogenic tyrosine kinases to induce cancer progression. Suppressing the function or expression of Grb2 should interrupt its vital signaling function and have a therapeutic application in cancer.